Equities research analysts expect that Soleno Therapeutics Inc (NASDAQ:SLNO) will announce ($0.19) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Soleno Therapeutics’ earnings. Soleno Therapeutics reported earnings per share of ($0.36) during the same quarter last year, which suggests a positive year over year growth rate of 47.2%. The company is scheduled to report its next earnings results on Tuesday, August 13th.

According to Zacks, analysts expect that Soleno Therapeutics will report full year earnings of ($0.77) per share for the current year. For the next year, analysts expect that the firm will post earnings of ($0.99) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Soleno Therapeutics.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.07.

A number of research firms have recently issued reports on SLNO. Laidlaw began coverage on shares of Soleno Therapeutics in a research note on Monday, July 8th. They set a “buy” rating and a $10.00 target price for the company. Zacks Investment Research cut shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday, July 17th. Finally, ValuEngine upgraded shares of YPF from a “sell” rating to a “hold” rating in a research note on Monday, June 24th.

In other Soleno Therapeutics news, major shareholder Bioasia Mangement Llc sold 90,724 shares of Soleno Therapeutics stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $1.93, for a total value of $175,097.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 43.27% of the company’s stock.

A number of institutional investors have recently modified their holdings of SLNO. Virtu Financial LLC acquired a new stake in Soleno Therapeutics in the 1st quarter worth about $72,000. Trellus Management Company LLC raised its stake in Soleno Therapeutics by 42.1% in the 1st quarter. Trellus Management Company LLC now owns 240,645 shares of the company’s stock worth $496,000 after purchasing an additional 71,265 shares in the last quarter. Finally, Fosun International Ltd raised its stake in Soleno Therapeutics by 4.7% in the 1st quarter. Fosun International Ltd now owns 188,982 shares of the company’s stock worth $397,000 after purchasing an additional 8,569 shares in the last quarter. Institutional investors and hedge funds own 46.08% of the company’s stock.

Shares of NASDAQ SLNO traded down $0.15 during mid-day trading on Monday, reaching $2.63. 41,400 shares of the company were exchanged, compared to its average volume of 748,476. The firm’s 50-day moving average is $2.76. The company has a market capitalization of $88.34 million, a PE ratio of -4.05 and a beta of 2.32. Soleno Therapeutics has a twelve month low of $1.11 and a twelve month high of $5.07.

About Soleno Therapeutics

Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc and changed its name to Soleno Therapeutics, Inc in May 2017.

Recommended Story: What is Cost of Goods Sold (COGS)?

Get a free copy of the Zacks research report on Soleno Therapeutics (SLNO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.